Peramivir
- Generic Name
- Peramivir
- Brand Names
- Rapivab
- Drug Type
- Small Molecule
- Chemical Formula
- C15H28N4O4
- CAS Number
- 330600-85-6
- Unique Ingredient Identifier
- 9ZS94HQO3B
- Background
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
- Indication
Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.
- Associated Conditions
- Acute, uncomplicated Influenza
NanoViricides' Broad-Spectrum Antiviral NV-387 Advances to Phase II Trials for MPox Treatment
• NanoViricides has received approval from the Democratic Republic of Congo's National Ethics Committee to proceed with Phase II clinical trials of NV-387 for MPox treatment, addressing a significant unmet need as no effective treatment currently exists.
• NV-387 employs a revolutionary host-mimetic mechanism that "looks like a cell" to viruses, potentially making it effective against 90-95% of human pathogenic viruses while being highly resistant to viral escape mutations.
• The drug has demonstrated superior efficacy in animal models against multiple viruses including influenza, RSV, coronavirus, and orthopoxviruses, outperforming existing treatments like Tamiflu, remdesivir, and matching tecovirimat against MPox-like infections.
BioCryst's Orladeyo Demonstrates Safety and Efficacy in Pediatric Hereditary Angioedema Trial
• Interim analysis of APeX-P trial shows Orladeyo (berotralstat) oral granule formulation is safe and well-tolerated in children aged 2-12 years with hereditary angioedema.
• Real-world evidence demonstrates significant reduction in HAE attack rates across patients with both C1-INH deficiency and normal C1-INH levels after Orladeyo initiation.
• Patient-reported outcomes indicate high treatment satisfaction and reduced attack frequency and severity, with 54% of U.S. participants maintaining Orladeyo treatment for over one year.
NanoViricides' NV-387 Shows Promise Against Multiple Viral Threats Following Successful Phase I Trial
• NanoViricides has completed Phase I clinical trials for NV-387 with no reported adverse events, demonstrating potential as a broad-spectrum antiviral against MPox, RSV, influenza, and COVID-19.
• The company's novel drug candidate NV-387 showed superior efficacy compared to existing treatments for influenza and demonstrated promising results against lethal RSV infections in preclinical studies.
• NanoViricides is preparing to advance NV-387 into Phase II trials for multiple indications, including MPox infections and Viral Acute Respiratory Infections, while positioning the drug as a potential countermeasure against emerging H5N1 bird flu threats.
Krystal Biotech and CRISPR Therapeutics Announce Key Updates in Gene Therapy Programs
• Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.
• Krystal Biotech's KB407 for cystic fibrosis received full sanctioning for its Phase 1 CORAL-1 study, with interim molecular data expected mid-2025.
• CRISPR Therapeutics reported positive momentum in the CASGEVY launch, with over 50 activated treatment centers and patients initiating cell collection globally.
• CRISPR Therapeutics expects key clinical data updates in 2025 for CTX112 in oncology and autoimmune diseases, and for CTX310 and CTX320 in cardiovascular programs.
NanoViricides' NV-387 Advances to Phase II Trials for Multiple Viral Infections
• NanoViricides' broad-spectrum antiviral NV-387 is set to advance to Phase II clinical trials, targeting MPOX, RSV, influenza, and COVID-19 infections.
• A Phase Ia/Ib trial of NV-387 was completed with no adverse events reported, showing promising results and paving the way for further clinical development.
• NV-387 has demonstrated superior effectiveness in animal trials compared to existing treatments for various viral infections, offering a potential breakthrough.
• The company faces funding challenges for Phase II trials despite recent capital raises, highlighting the need for additional financial resources.
NanoViricides' NV-387 Advances to Phase II Clinical Trials for MPox Treatment
• NanoViricides has engaged a CRO to initiate a Phase II clinical trial for NV-387, a broad-spectrum antiviral drug.
• The trial will assess NV-387's effectiveness in treating MPox patients amidst a regional pandemic in Africa.
• NV-387 has demonstrated strong antiviral activity against orthopoxviruses in animal models, showing potential against MPox and Smallpox.
• The drug's unique mechanism mimics cell entry pathways, potentially preventing virus escape and offering a revolutionary approach.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath